title: Advances in prodrug design.
abstract: The background of prodrug design is presented herein as the basis for introducing new and advanced latent systems, taking into account mainly the versatility of polymers and other macromolecules as carriers. PDEPT (Polymer-Directed Enzyme Prodrug Therapy); PELT (Polymer-Enzyme Liposome Therapy); CDS (Chemical Delivery System); ADEPT(Antibody-Directed Enzyme Prodrug Therapy); GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Virus-Directed Enzyme Prodrug Therapy); ODDS (Osteotropic Drug Delivery System) and LEAPT (Lectin-directed enzyme-activated prodrug therapy) are briefly described and some examples are given.
authors.affiliation: Laboratório de Pesquisa e Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciencias Farmacee, UNESP, Araraquara, Brazil.
authors.forename: Antonio Távora de Albuquerque
authors.initials: AT
authors.lastname: Silva
authors.forename: Man Chin
authors.initials: MC
authors.lastname: Chung
authors.forename: Lúcia Fioravanti
authors.initials: LF
authors.lastname: Castro
authors.forename: Rafael Victorio Carvalho
authors.initials: RV
authors.lastname: Güido
authors.forename: Elizabeth Igne
authors.initials: EI
authors.lastname: Ferreira
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015195:Drug Design; D015316:Genetic Therapy; D006801:Humans; D037102:Lectins / Q000627:therapeutic use; D046911:Macromolecular Substances / Q000008:administration & dosage* / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy; D011355:Prodrugs / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D014780:Viruses / Q000276:immunology
chemical_list: D000906:Antibodies; D004337:Drug Carriers; D037102:Lectins; D046911:Macromolecular Substances; D011355:Prodrugs